References

russjcardiol

Российский кардиологический журнал

Russian Journal of Cardiology

1560-40712618-7620

«SILICEA-POLIGRAF» LLC

10.15829/1560-4071-2024-6117

GUEWLU

russjcardiol-6117

Research Article

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

CLINICAL GUIDELINES

Артериальная гипертензия у взрослых. Клинические рекомендации 2024

2024 Clinical practice guidelines for Hypertension in adults

Кобалава

Ж. Д.

Kobalava

Zh. D.

Член-корр. РАН, профессор, д.м.н.

Москва

cardiojournal@yandex.ru

Конради

А. О.

Konradi

A. O.

Академик РАН, профессор, д.м.н.

Санкт-Петербург

Недогода

С. В.

Nedogoda

S. V.

Профессор, д.м.н.

Волгоград

Шляхто

Е. В.

Shlyakhto

E. V.

Академик РАН, профессор, д.м.н.

Санкт-Петербург

Арутюнов

Г. П.

Arutyunov

G. P.

Член-корр. РАН, профессор, д.м.н.

Москва

Баранова

Е. И.

Baranova

E. I.

Профессор, д.м.н.

Санкт-Петербург

Барбараш

О. Л.

Barbarash

O. L.

Академик РАН, профессор, д.м.н.

Кемерово

Бобкова

Н. В.

Bobkova

N. V.

Доцент, д.м.н.

Москва

Бойцов

С. А.

Boytsov

S. A.

Академик РАН, профессор, д.м.н.

Москва

Бубнова

М. Г.

Bubnova

M. G.

Профессор, д.м.н.

Москва

Вавилова

Т. В.

Vavilova

T. V.

Профессор, д.м.н.

Москва

Виллевальде

С. В.

Villevalde

S. V.

Профессор, д.м.н.

Санкт-Петербург

Галявич

А. С.

Galyavich

A. S.

Профессор, д.м.н.

Казань

Глезер

М. Г.

Glezer

M. G.

Профессор, д.м.н.

Москва

Гринева

Е. Н.

Grineva

E. N.

Профессор, д.м.н.

Санкт-Петербург

Гринштейн

Ю. И.

Grinstein

Yu. I.

Профессор, д.м.н.

Красноярск

Драпкина

О. М.

Drapkina O. M.,

O. M.

Академик РАН, профессор, д.м.н.

Москва

Жернакова

Ю. В.

Zhernakova

Yu. V.

Профессор, д.м.н.

Москва

Звартау

Н. Э.

Zvartau

N. E.

Доцент, д.м.н.

Санкт-Петербург

Иртюга

Щ. Б.

Irtyuga

O. B.

Доцент, д.м.н.

Санкт-Петербург

recommendation@scardio.ru

Кисляк

О. А.

Kislyak

O. A.

Профессор, д.м.н

Москва

Козиолова

Н. А.

Koziolova

N. A.

Профессор, д.м.н.

Пермь

Космачева

Е. Д.

Kosmacheva

E. D.

Профессор, д.м.н.

Краснодар

Котовская

Ю. В.

Kotovskaya Yu. V.,

Yu. V.

Профессор, д.м.н.

Москва

Либис

Р. А.

Libis

R. A.

Профессор, д.м.н.

Оренбург

Лопатин

Ю. М.

Lopatin

Yu. M.

Член-корр. РАН, профессор, д.м.н.

Волгоград

Небиеридзе

Д. В.

Nebiridze

D. V.

Профессор, д.м.н.

Москва

Недошивин

А. О.

Nedoshivin

A. O.

Профессор, д.м.н.

Санкт-Петербург

Никулина

С. Ю.

Nikulina

S. Yu.

Профессор, д.м.н.

Красноярск

Остроумова

О. Д.

Ostroumova

O. D.

Профессор, д.м.н.

Москва

Ощепкова

Е. В.

Oschepkova

E. V.

Профессор, д.м.н.

Москва

Ратова

Л. Г.

Ratova

L. G.

Профессор, к.м.н.

Санкт-Петербург

Саласюк

Ф. С.

Salasiuk

A. S.

Д.м.н.

Москва

Скибицкий

В. В.

Skibitsky

V. V.

Профессор, д.м.н.

Москва

Ткачева

О. Н.

Tkacheva

O. N.

Член-корр. РАН, профессор, д.м.н.

Москва

Троицкая

Е. А.

Troitskaya

E. A.

Доцент, к.м.н.

Москва

Чазова

И. Е.

Chazova

I. E.

Академик РАН, профессор, д.м.н.

Москва

Чесникова

Е. И.

Chesnikova

A. I.

Профессор, д.м.н.

Ростов-на-Дону

Чумакова

Г. А.

Chumakova

G. A.

Профессор, д.м.н.

Барнаул

Шальнова

С. А.

Shalnova

S. A.

Профессор, д.м.н.

Москва

Шестакова

М. В.

Shestakova

M. V.

Академик РАН, профессор, д.м.н.

Москва

Якушин

С. С.

Yakushin

S. S.

Профессор, д.м.н.

Рязань

Янишевский

С. Н.

Yanishevsky

S. N.

Профессор, д.м.н.

Москва

2024

09092024

29961176117

Copyright © Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И., Барбараш О.Л., Бобкова Н.В., Бойцов С.А., Бубнова М.Г., Вавилова Т.В., Виллевальде С.В., Галявич А.С., Глезер М.Г., Гринева Е.Н., Гринштейн Ю.И., Драпкина О.М., Жернакова Ю.В., Звартау Н.Э., Иртюга Щ.Б., Кисляк О.А., Козиолова Н.А., Космачева Е.Д., Котовская Ю.В., Либис Р.А., Лопатин Ю.М., Небиеридзе Д.В., Недошивин А.О., Никулина С.Ю., Остроумова О.Д., Ощепкова Е.В., Ратова Л.Г., Саласюк Ф.С., Скибицкий В.В., Ткачева О.Н., Троицкая Е.А., Чазова И.Е., Чесникова Е.И., Чумакова Г.А., Шальнова С.А., Шестакова М.В., Якушин С.С., Янишевский С.Н., 2024

2024

Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И., Барбараш О.Л., Бобкова Н.В., Бойцов С.А., Бубнова М.Г., Вавилова Т.В., Виллевальде С.В., Галявич А.С., Глезер М.Г., Гринева Е.Н., Гринштейн Ю.И., Драпкина О.М., Жернакова Ю.В., Звартау Н.Э., Иртюга Щ.Б., Кисляк О.А., Козиолова Н.А., Космачева Е.Д., Котовская Ю.В., Либис Р.А., Лопатин Ю.М., Небиеридзе Д.В., Недошивин А.О., Никулина С.Ю., Остроумова О.Д., Ощепкова Е.В., Ратова Л.Г., Саласюк Ф.С., Скибицкий В.В., Ткачева О.Н., Троицкая Е.А., Чазова И.Е., Чесникова Е.И., Чумакова Г.А., Шальнова С.А., Шестакова М.В., Якушин С.С., Янишевский С.Н.

Kobalava Z.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I., Barbarash O.L., Bobkova N.V., Boytsov S.A., Bubnova M.G., Vavilova T.V., Villevalde S.V., Galyavich A.S., Glezer M.G., Grineva E.N., Grinstein Y.I., Drapkina O. M., O.M., Zhernakova Y.V., Zvartau N.E., Irtyuga O.B., Kislyak O.A., Koziolova N.A., Kosmacheva E.D., Kotovskaya Yu. V., Y.V., Libis R.A., Lopatin Y.M., Nebiridze D.V., Nedoshivin A.O., Nikulina S.Y., Ostroumova O.D., Oschepkova E.V., Ratova L.G., Salasiuk A.S., Skibitsky V.V., Tkacheva O.N., Troitskaya E.A., Chazova I.E., Chesnikova A.I., Chumakova G.A., Shalnova S.A., Shestakova M.V., Yakushin S.S., Yanishevsky S.N.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://russjcardiol.elpub.ru/jour/article/view/6117

Российское кардиологическое общество (РКО)

При участии: Российского научного медицинского общества терапевтов (РНМОТ)

The Russian Society of Cardiology (RKO)

With the participation of: Russian Scientific Medical Society of Internal Medicine (RSMSIM)

Approved by the Research and Practical Council of the Ministry of Health of the Russian Federation (12.09.2024)

артериальная гипертензиягипертоническая болезньклассификация артериальной гипертензииартериальное давлениерекомендацииизмерение артериального давленияцелевые значения артериального давлениямедикаментозная терапия артериальной гипертензиигипертонический кризсердечно-сосудистый рисксердечно-сосудистые заболевания

References1

Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312(7023):71-2. doi:10.1136/bmj.312.7023.71.

Jansen RW, Lipsitz LA. Postprandial hypotension: epidemiology, pathophysiology, and clinical management. Ann Int Med. 1995;122(4):286-95.

Андреева Н.С., Реброва О.Ю., Зорин Н.А. и др. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор. 2012;(4):10-24.

Andreeva NS, Rebrova OYu, Zorin NA, et al. Systems for assessing the reliability of scientific evidence and the credibility of recommendations: comparative characteristics and prospects for unification. Medical technologies. Assessment and selection. 2012;(4):10- 24. (In Russ.)

Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014;383(9932):1899-911. doi:10.1016/S0140-6736(14)60685-1.

Ehret GB, Caulfield MJ. Genes for blood pressure: an opportunity to understand hypertension. Eur Heart J. 2013;34:951-61.

Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874- 2071. doi:10.1097/HJH.0000000000003480. Erratum in: J Hypertens. 2024;42(1):194. doi:10.1097/HJH.0000000000003621.

Elliott P, Stamler J, Nichols R, et al. Intersalt revisited: further analyses of 24 hour so - dium excretion and blood. pressure within and across populations. Intersalt Cooperative Research Group. BMJ. 1996;312:1249-53.

Guo Y, Li X, Wang Z, Yu B. Gut Microbiota Dysbiosis in Human Hypertension: A Systematic Review of Observational Studies. Front Cardiovasc Med. 2021;8:650227. doi:10.3389/fcvm.2021.650227.

Wilck N, Matus MG, Kearney SM, et al. Salt-responsive gut commensal modulates TH17 axis and disease. Nature. 2017;551(7682):585-9. doi:10.1038/nature24628.

Griendling KK, Camargo LL, Rios FJ, et al. Oxidative stress and hypertension. Circ Res. 2021;128:993-1020.

Кушаковский М.С. Эссенциальная гипертензия (гипертоническая болезнь): Причины, механизмы, клиника, лечение. 5. изд., существенно доп. и перераб. СПб.: Фолиант, 2002. 414 с. ISBN: 5-93929-045-0.

Kushakovsky MS. Essential hypertension (hypertension): Causes, mechanisms, clinic, treatment. 5. ed., substantially additional and revised St.Petersburg : Folio, 2002. 414 p. (In Russ.) ISBN: 5-93929-045-0.

Ланг Г.Ф. Гипертоническая болезнь. М.: Медгиз, 1950. 459 с.

Lang GF. Hypertension. M.: Medgiz, 1950. 459 p. (In Russ.)

Постнов Ю.В., Орлов С.Н. Первичная гипертензия как патология клеточных мембран. М.: Медицина, 1987. 192 с.

Postnov YuV, Orlov SN. Primary hypertension as a pathology of cell membranes. M.: Medicine, 1987. 192 p. (In Russ.)

Мясников А.Л. Гипертоническая болезнь. М.: Медгиз, 1954.

Myasnikov AL. Hypertension. M.: Medgiz, 1954. (In Russ.)

Page IH. Pathogenesis of arterial hypertension. J Am Med Assoc. 1949;140:451-8.

Муромцева Г.А., Концевая А.В., Константинов В.В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика 2014;13(6):4-11.

Muromtseva GA, Kontsevaya AV, Konstantinov VV, et al. The prevalence of noninfectious diseases risk factors in russian population in 2012-2013 years. The results of ECVD-RF. Cardiovascular Therapy and Prevention. 2014;13(6):4-11. (In Russ.)

Бойцов С.А., Баланова Ю.А., Шальнова С.А. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;13(4):4-14.

Boytsov SA, Balanova YuA, Shalnova SA, et al. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. (In Russ.)

Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-23.

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. NCD Risk Factor Collaboration (NCD-RisC). Lancet. 2021;398:957- 80. doi:10.1016/S0140-6736(21)01330-1.

Franklin SS, Lopez VA, Wong ND, et al. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119:243-50.

Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension:, The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041.

Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13.

Lip GYH, Coca A, Kahan T, et al. Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Eur Heart J Cardiovasc Pharmacother. 2017;3:235-50.

Gottesman RF, Albert MS, Alonso A, et al. Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA Neurol. 2017;74:1246-54.

Rovio SP, Pahkala K, Nevalainen J, et al. Cardiovascular risk factors from childhood and midlife cognitive performance: the Young Finns study. J Am Coll Cardiol. 2017;69:2279-89.

Vishram JK, Borglykke A, Andreasen AH, et al, MORGAM Project. Impact of age on the importance of systolic and diastolic blood pressures for stroke risk: the MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) project. Hypertension. 2012;60: 1117-23.

Brown DW, Giles WH, Greenlund KJ. Blood pressure parameters and risk of fatal stroke, NHANES II mortality study. Am J Hypertens. 2007;20:338-41.

Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation. 1999;100:354-60.

Domanski M, Mitchell G, Pfeffer M, et al., MRFIT Research Group. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 2002;287:2677-83.

Кобалава Ж.Д., Конради А.О., Недогода С.В. и др. Меморандум экспертов Российского кардиологического общества по рекомендациям Европейского общества кардиологов/Европейского общества по артериальной гипертензии по лечению артериальной гипертензии, 2018 г. Российский кардиологический журнал. 2018;(12):131-42. doi:10.15829/1560-4071-2018-12-131-142.

Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Russian Society of Cardiology position paper on 2018 Guidelines of the European Society of Cardiology/European Society of Arterial Hypertension for the management of arterial hypertension. Russian Journal of Cardiology. 2018;(12):131-42. (In Russ.) doi:10.15829/1560-4071-2018-12-131-142.

Reino-Gonzalez S, Pita-Fernández S, Seoane-Pillado T, et al. How in-office and ambulatory BP monitoring compare: A systematic review and meta-analysis. J Fam Pract. 2017;66(1):E5-E12.

Kollias A, Ntineri A, Stergiou GS. Association of night-time home blood pressure with night-time ambulatory blood pressure and target-organ damage: a systematic review and meta-analysis. J Hypertens. 2017;35(3):442-52. doi:10.1097/HJH.0000000000001189.

Fagard RH, Celis H, Thijs L, et al. Daytime and night-time blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51:55-61.

Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens. 2012;30:449-56.

Mancia G, Facchetti R, Bombelli M, et al. Long-term risk of mortality associated with selective and combined elevation in office, home and ambulatory blood pressure. Hypertension. 2006;47:846-53.

Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension vs. true normotension: a meta-analysis. J Hypertens. 2007;25: 2193-8. doi:10.1097/HJH.0b013e3282ef6185.

Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35:1245-54.

Carey RM, Calhoun DA, Bakris GL. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018;72(5):e53-e90.

Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105:98-105.

Albasri A, OʼSullivan JW, Roberts NW, et al. A comparison of blood pressure in community pharmacies with ambulatory, home and general practitioner office readings: systematic review and meta-analysis. J Hypertens. 2017;35(10):1919-28. doi:10.1097/HJH.0000000000001443.

Sega R, Facchetti R, Bombelli M, et al.Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111:1777-83.

Stergiou GS, Palatini P, Asmar R, et al. Blood pressure monitoring: theory and practice. European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability Teaching Course Proceedings. Blood Press Monit. 2018;23(1): 1-8. doi:10.1097/MBP.0000000000000301.

Stergiou GS, Mukkamala R, Avolio A, et al.; European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. Cuffless blood pressure measuring devices: review and statement by the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. J Hypertens. 2022;40(8):1449-60. doi:10.1097/HJH.0000000000003224.

Clark CE, Taylor RS, Shore AC, et al. Association of a difference in systolic blood pressure between arms with vascular disease and mortality: a systematic review and meta-analysis. Lancet. 2012;379:905-14.

Tucker KL, Sheppard JP, Stevens R, et al. Self-monitoring of blood pressure in hypertension: a systematic review and individual patient data meta-analysis. PLoS Med. 2017;14:e1002389.

Yang WY, Melgarejo JD, Thijs L, et al.; International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators. Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes. JAMA. 2019;322(5):409-20. doi:10.1001/jama.2019.9811.

Fujiwara T, Hoshide S, Kanegae H, Kario K. Cardiovascular event risks associated with masked nocturnal hypertension defined by home blood pressure monitoring in the J-HOP Nocturnal Blood Pressure Study. Hypertension. 2020;76:259-66.

Parati G, Bilo G, Kollias A, et al. Blood pressure variability: methodological aspects, clinical relevance and practical indications for management — a European Society of Hypertension position paper 0. J Hypertens 2023;41:527-44.

Wang N, Harris K, Hamet P, et al. Cumulative systolic blood pressure load and cardiovascular risk in patients with diabetes. J Am Coll Cardiol. 2022;80:1147-55.

Mahfoud F, Mancia G, Schmieder RE, et al. Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range. J Am Coll Cardiol. 2022;80:1871-80.

Cheng YB, Thijs L, Aparicio LS, et al. Risk stratification by cross-classification of central and brachial systolic blood pressure. Hypertension. 2022;79:1101-11.

Sharman JE, Avolio AP, Baulmann J, et al. Validation of noninvasive central blood pressure devices: ARTERY Society task force consensus statement on protocol standardization. Eur Heart J. 2017;38:2805-12.

Palatini P, Rosei EA, Avolio A, et al. Isolated systolic hypertension in the young: a position paper endorsed by the European Society of Hypertension. J Hypertens. 2018;36(6): 1222-36. doi:10.1097/HJH.0000000000001726.

Kario K. Orthostatic hypertension-a new haemodynamic cardiovascular risk factor. Nat Rev Nephrol. 2013;9:726-38.

Kostis WJ, Sargsyan D, Mekkaoui C, et al. Association of orthostatic hypertension with mortality in the Systolic Hypertension in the Elderly Program. J Hum Hypertens. 2019;33:735-40.

Dani M, Dirksen A, Taraborrelli P, et al. Orthostatic hypotension in older people: considerations, diagnosis and management. Clin Med (Lond). 2021;21:e275-e282.

SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021;42(25):2455-67. doi:10.1093/eurheartj/ehab312.

SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439-54. doi:10.1093/eurheartj/ehab309.

Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane Database Syst Rev. 2014;(6):CD007333. doi:10.1002/14651858.CD007333.pub2.

Black C, Sharma P, Scotland G, et al. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis., Health Technol Assess 2010;14(21):1-184. doi:10.3310/hta14210.

Chan MR, Dall AT, Fletcher KE, et al. Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis. Am J Med. 2007;120(12):1063-70. doi:10.1016/j.amjmed.2007.04.024.

Hunt SC, Williams RR, Barlow GK. A comparison of positive family history definitions for defining risk of future disease. J Chronic Dis. 1986; 39:809-21.

Friedman GD, Selby JV, Quesenberry CP Jr, et al. Precursors of essential hypertension: body weight, alcohol and salt use and parental history of hypertension. Prev Med. 1988;17:387-402.

Shi Y, Zhou W, Liu X, et al. Resting heart rate and the risk of hypertension and heart failure: a dose-response meta-analysis of prospective studies. J Hypertens. 2018;36(5):995- 1004. doi:10.1097/HJH.0000000000001627.

Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 10-й выпуск. Сахарный диабет. 2021;24(1S):1-148. doi:10.14341/DM12802.

Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 10th edition. Diabetes mellitus. 2021;24(1S):1-148. (In Russ.) doi:10.14341/DM12802.

Cosentino F, Grant PJ, Aboyans V, et al.; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486. Erratum in: Eur Heart J. 2020;41(45):4317. doi:10.1093/eurheartj/ehz828.

Emerging Risk Factors Collaboration; Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22. doi:10.1016/S0140-6736(10)60484-9. Erratum in: Lancet. 2010;376(9745):958.

Wilson PW, Cupples CF, Kannel WB. Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Amer. Heart J. 1991;121:586-90.

Izzo R, de Simone G, Trimarco V, et al. Hypertensive target organ damage predicts incident diabetes mellitus. Eur Heart J. 2013;34(44):3419-26. doi:10.1093/eurheartj/eht281.

Matsushita K, Mahmoodi BK, Woodward M, et al.; Chronic Kidney Disease Prognosis Consortium. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012;307(18):1941-51. doi:10.1001/jama.2012.3954.

de Haan MW, Kroon AA, Flobbe K, et al. Renovascular disease in patients with hypertension: detection with duplex ultrasound. J Hum Hypertens. 2002;16(7):501-7. doi:10.1038/sj.jhh.1001429.

Mahmoodi BK, Matsushita K, Woodward M, et al.; Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012;380(9854):1649-61. doi:10.1016/S0140-6736(12)61272-0. Erratum in: Lancet. 2012;380(9854):1648.

van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79(12):1341-52. doi:10.1038/ki.2010.536.

Earley A, Miskulin D, Lamb EJ, et al. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med. 2012;156:785-95.

Zachrisson K, Herlitz H, Lönn L, Falkenberg M, Eklöf H. Duplex ultrasound for identifying renal artery stenosis: direct criteria re-evaluated. Acta Radiol. 2017;58(2):176-82. doi:10.1177/0284185116641345.

Matsushita K, Coresh J, Sang Y, et al.; CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514- 25. doi:10.1016/S2213-8587(15)00040-6.

Gerstein HC, Mann JF, Yi Q, Zinman B, et al. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-6.

Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12):1302-9. doi:10.1001/jama.2012.366. Erratum in: JAMA. 2012;307(16):1694. Erratum in: JAMA. 2012;307(18):1915.

Caggiula AW, Christakis G, Farrand M, et al. The multiple risk intervention trial (MRFIT). IV. Intervention on blood lipids. Prev Med. 1981;10(4):443-75. doi:10.1016/0091-7435(81)90060-8.

Prospective Studies Collaboration; Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829-39. doi:10.1016/S0140-6736(07)61778-4. Erratum in: Lancet. 2008;372(9635):292.

Geleijnse JM, Kok FJ, Grobbee DE. Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. J Hum Hypertens. 2003;17(7):471-80. doi:10.1038/sj.jhh.1001575.

Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol. 2004;43(2):155-61. doi:10.1016/j.jacc.2003.06.021.

Wang J, Qin T, Chen J, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One. 2014;9(12):e114259. doi:10.1371/journal.pone.0114259.

Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63(1):102-10. doi:10.1002/acr.20344.

Palmer TM, Nordestgaard BG, Benn M, et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ. 2013;347:f4262. doi:10.1136/bmj.f4262.

Lehtonen AO, Puukka P, Varis J, et al. Prevalence and prognosis of ECG abnormalities in normotensive and hypertensive individuals. J Hypertens. 2016;34:959-66.

Vanezis AP, Bhopal R. Validity of electrocardiographic classification of left ventricular hypertrophy across adult ethnic groups with echocardiography as a standard. J Electrocardiol. 2008;41(5):404-12. doi:10.1016/j.jelectrocard.2008.02.013.

Schillaci G, Battista F, Pucci G. A review of the role of electrocardiography in the diagnosis of left ventricular hypertrophy in hypertension. J Electrocardiol. 2012;45(6):617-23. doi:10.1016/j.jelectrocard.2012.08.051.

Kahn S, Frishman WH, Weissman S, et al. Left ventricular hypertrophy on electrocardiogram: prognostic implications from a 10-year cohort study of older subjects: a report from the Bronx Longitudinal Aging Study. J Am Geriatr Soc. 1996;44:524-9.

Okin PM, Devereux RB, Jern S, et al. LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343-9.

Verdecchia P, Angeli F, Borgioni C, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. American Journal of Hypertension. 2003;16(11 Pt 1):895-9. doi:10.1016/s0895-7061(03)01018-5.

Sundstrom J, Lind L, Arnlov J, et al. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation. 2001;103:2346-51.

Levy D, Garrison RJ, Savage DO, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-6.

Perrone-Filardi P, Coca A, Galderisi M, et al. Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH). Eur Heart J Cardiovasc Imaging. 2017;18:945-60.

Spittell PC, Ehrsam JE, Anderson L, Seward JB. Screening for abdominal aortic aneurysm during transthoracic echocardiography in a hypertensive patient population. J Am Soc Echocardiogr. 1997;10(7):722-7. doi:10.1016/s0894-7317(97)70115-9.

Aboyans V, Kownator S, Lafitte M et al.; Working Group for Vascular Diseases/Thrombosis, French Society of Cardiology; Council of Echocardiography, French Society of Cardiology. Screening abdominal aorta aneurysm during echocardiography: literature review and proposal for a French nationwide study. Arch Cardiovasc Dis. 2010;103(10):552-8. doi:10.1016/j.acvd.2010.06.003.

Shukha Y, Koren O, Or T, et al. Screening of Abdominal Aortic Aneurysm Using Portable Transthoracic Echocardiography among Patients with Acute Coronary Syndrome. Cardiol Res Pract. 2020;2020:9510546. doi:10.1155/2020/9510546.

Park HB. Clinical Usefulness of Additional Screening for Abdominal Aortic Aneurysm during Transthoracic Echocardiography. J Cardiovasc Imaging. 2020;28(4):265-6. doi:10.4250/jcvi.2020.0114.

Jahromi AS, Cinà CS, Liu Y, Clase CM. Sensitivity and specificity of color duplex ultrasound measurement in the estimation of internal carotid artery stenosis: a systematic review and meta-analysis. J Vasc Surg. 2005;41(6):962-72. doi:10.1016/j.jvs.2005.02.044.

100

Mourad JJ, Cacoub P, Collet JP, et al.; ELLIPSE scientific committee and study investigators. Screening of unrecognized peripheral arterial disease (PAD) using anklebrachial index in high cardiovascular risk patients free from symptomatic PAD. J Vasc Surg. 2009;50(3):572-80. doi:10.1016/j.jvs.2009.04.055.

101

Vlachopoulos C, Aznaouridis K, Terentes-Printzios D, et al. Prediction of cardiovascular events and all-cause mortality with brachial-ankle elasticity index: a systematic review and meta-analysis. Hypertension. 2012;60(2):556-62. doi:10.1161/HYPERTENSIONAHA.112.194779.

102

Fuchs FD, Maestri MK, Bredemeier M, et al. Study of the usefulness of optic fundi examination of patients with hypertension in a clinical setting. J Hum Hypertens. 1995;9(7):547-51.

103

Breslin DJ, Gifford RW Jr, Fairbairn JF II, Kearns TP. Prognostic importance of ophthalmoscopic findings in essential hypertension. JAMA. 1966;195:335-8.

104

Dimmitt SB, West JN, Eames SM, et al. Usefulness of ophthalmoscopy in mild to moderate hypertension. Lancet. 1989;1:1103-6.

105

White PM, Wardlaw JM, Easton V. Can noninvasive imaging accurately depict intracranial aneurysms? A systematic review. Radiology. 2000;217(2):361-70. doi:10.1148/radiology.217.2.r00nv06361.

106

Beynon R, Sterne JA, Wilcock G, et al. Is MRI better than CT for detecting a vascular component to dementia? A systematic review and meta-analysis. BMC Neurol. 2012;12:33. doi:10.1186/1471-2377-12-33.

107

Creavin ST, Wisniewski S, Noel-Storr AH, et al. Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Syst Rev. 2016;2016(1): CD011145. doi:10.1002/14651858.CD011145.pub2.

108

Tsoi KK, Chan JY, Hirai HW, et al. Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med. 2015;175:1450-8.

109

Mach F, Baigent C, Catapano AL, et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. doi:10.1093/eurheartj/ehz455. Erratum in: Eur Heart J. 2020;41(44):4255. doi:10.1093/eurheartj/ehz826.

110

Ebrahim S, Smith GD. Lowering blood pressure: a systematic review of sustained effects of non-pharmacological interventions. J Public Health Med. 1998;20(4):441-8. doi:10.1093/oxfordjournals.pubmed.a024800.

111

Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387: 957-67.

112

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels — updated overview and meta-analyses, of randomized trials. J Hypertens. 2016;34:613-22.

113

Thomopoulos C. Target blood pressure in isolated systolic hypertension: a metaanalysis of randomized outcome trials. J Hypertens. 2023;41(12):2113-4. doi:10.1097/HJH.0000000000003476.

114

Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-98.

115

Thijs L, Fagard R, Lijnen P, et al. A meta-analysis of outcome trials in elderly hypertensives. J Hypertens. 1992;10(10):1103-9. doi:10.1097/00004872-199210000-00001.

116

Lonn EM, Bosch J, Lopez-Jaramillo P, et al. HOPE-3 Investigators. Blood-pressure lowering in. intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009-20.

117

Agarwal R, Bills JE, Hecht TJ, Light RP. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and metaanalysis. Hypertension. 2011;57(1):29-38. doi:10.1161/HYPERTENSIONAHA.110.160911.

118

Sundstrom J, Arima H, Jackson R, et al. Blood Pressure-Lowering Treatment Trialists’ Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med. 2015;162:184-91.

119

Visseren FLJ, Mach F, Smulders YM, et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-37. doi:10.1093/eurheartj/ehab484. Erratum in: Eur Heart J. 2022;43(42):4468. doi:10.1093/eurheartj/ehac458.

120

Williamson JD, Supiano MA, Applegate WB, et al. SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA. 2016;315:2673-82.

121

Beckett N, Peters R, Leonetti G, et al., HYVET Study Group. Subgroup and per-protocol analyses from the Hypertension in the Very Elderly Trial. J Hypertens. 2014;32:1478-87.

122

Jaeger BC, Bress AP, Bundy JD, et al. Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2022;7(11):1138-46. doi:10.1001/jamacardio.2022.3345.

123

Hao G, Wang Z, Guo R, et al. Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies. BMC Cardiovasc Disord. 2014;14:148. doi:10.1186/1471-2261-14-148.

124

Garrison SR, Kolber MR, Korownyk CS, et al. Blood pressure targets for hypertension in older adults. Cochrane Database Syst Rev. 2017;8(8):CD011575. doi:10.1002/14651858.CD011575.pub2.

125

Mancia G, Giannattasio C. Diagnostic and therapeutic problems of isolated systolic hypertension. J Hypertens. 2015;33:33-43.

126

Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology, American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13-e115. doi:10.1161/308.HYP.0000000000000065.

127

Benetos A, Bulpitt CJ, Petrovic M, et al. An Expert Opinion From the European Society of Hypertension-European Union Geriatric Medicine Society Working Group on the Management of Hypertension in Very Old, Frail Subjects. Hypertension. 2016;67(5):820- 5. doi:10.1161/HYPERTENSIONAHA.115.07020.

128

Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006;24:215-33.

129

Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990- 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224-60. doi:10.1016/S0140-6736(12)61766-8. Erratum in: Lancet. 2013;381(9874):1276. Erratum in: Lancet. 2013;381(9867):628. AlMazroa, Mohammad A [added]; Memish, Ziad A [added].

130

He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. 2013;4:CD004937.

131

Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low-sodium diet vs. highsodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). Am J Hypertens. 2012;25:1-15.

132

Taylor RS, Ashton KE, Moxham T, et al. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review). Am J Hypertens. 2011;24:843-53.

133

Aburto NJ, Ziolkovska A, Hooper L, et al. Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ. 2013;346:f1326.

134

Neal B, Wu Y, Feng X, et al. Effect of Salt Substitution on Cardiovascular Events and Death. N Engl J Med. 2021;385(12):1067-77. doi:10.1056/NEJMoa2105675.

135

Xin X, He J, Frontini MG, Ogden LG, et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2001;38(5):1112-7. doi:10.1161/hy1101.093424.

136

Gay HC, Rao SG, Vaccarino V, Ali MK. Effects of Different Dietary Interventions on Blood Pressure: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Hypertension. 2016;67(4):733-9. doi:10.1161/HYPERTENSIONAHA.115.06853.

137

Filippini T, Naska A, Kasdagli MI, et al. Potassium intake and blood pressure: a dose-response meta-analysis of randomized controlled trials. J Am Heart Assoc. 2020;9:e015719.

138

Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ. 2013;346:f1378.

139

Poorolajal J, Zeraati F, Soltanian AR, et al. Oral potassium supplementation for management of essential hypertension: A meta-analysis of randomized controlled trials. PLoS One. 2017;12(4):e0174967. doi:10.1371/journal.pone.0174967.

140

Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a metaanalysis of randomized controlled trials.Hypertension. 2003;42:878-84.

141

Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71-82.

142

Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;363(23):2211-9. doi:10.1056/NEJMoa1000367. Erratum in: N Engl J Med. 2011;365(9):869.

143

Leitzmann MF, Park Y, Blair A, et al. Physical activity recommendations and decreased risk of mortality. Arch Intern Med. 2007;167(22):2453-60. doi:10.1001/archinte.167.22.2453.

144

Rossi A, Dikareva A, Bacon SL, Daskalopoulou SS. The impact of physical activity on mortality in patients with high blood pressure: a systematic review. J Hypertens. 2012;30(7):1277-88. doi:10.1097/HJH.0b013e3283544669.

145

Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ. 1989;298(6676):789-94. doi:10.1136/bmj.298.6676.789.

146

He J, Vupputuri S, Allen K, et al. Passive smoking and the risk of coronary heart diseasea meta-analysis of epidemiologic studies. N Engl J Med. 1999;340(12):920-6. doi:10.1056/NEJM199903253401204.

147

Linneberg A, Jacobsen RK, Skaaby T, et al. Effect of Smoking on Blood Pressure and Resting Heart Rate: A Mendelian Randomization Meta-Analysis in the CARTA Consortium. Circ Cardiovasc Genet. 2015;8(6):832-41. doi:10.1161/CIRCGENETICS.115.001225.

148

Matsuzaki M, Ogihara T, Umemoto S, et al. Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens. 2011;29:1649-59.

149

MacDonald TM, Williams B, Webb DJ, et al. British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm-based Therapy (PATHWAY)., Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. J Am Heart Assoc 2017;6:e006986.

150

Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59:1124-31.

151

Corrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens. 2010;28:1584-90.

152

Garjón J, Saiz LC, Azparren A, et al. First-line combination therapy versus firstline monotherapy for primary hypertension. Cochrane Database Syst Rev. 2017;1(1):CD010316. doi:10.1002/14651858.CD010316.pub2. Update in: Cochrane Database Syst Rev. 2020;2:CD010316. doi:10.1002/14651858.CD010316.pub3.

153

Hermida RC, Crespo JJ, Domínguez-Sardiña M, et al; Hygia Project Investigators. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. 2020;41(48):4565-76. doi:10.1093/eurheartj/ehz754.

154

Poulter NR, Savopoulos C, Anjum A, et al. Randomized Crossover Trial of the Impact of Morning or Evening Dosing of Antihypertensive Agents on 24-Hour Ambulatory Blood Pressure. Hypertension. 2018;72(4):870-3. doi:10.1161/HYPERTENSIONAHA.118.11101.

155

Mackenzie IS, Rogers A, Poulter NR, et al; TIME Study Group. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint, clinical trial. Lancet. 2022;400(10361):1417-25. doi:10.1016/S0140-6736(22)01786-X.

156

Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig. 2012;32:649-64.

157

Pongpanich P, Pitakpaiboonkul P, Takkavatakarn K, et al. The benefits of angiotensinconverting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis. Int Urol Nephrol. 2018;50(12):2261-78. doi:10.1007/s11255-018-1991-x.

158

Makani H, Bangalore S, Desouza KA, et al. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ. 2013;346:f360. doi:10.1136/bmj.f360.

159

Fried LF, Emanuele N, Zhang JH, et al. NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369: 1892-903.

160

Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators, Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-59.

161

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs — overview and meta-analyses. J Hypertens. 2015;33:1321-41.

162

Reboldi G, Angeli F, Cavallini C, et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. 2008;26(7):1282-9. doi:10.1097/HJH.0b013e328306ebe2.

163

Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. J Hypertens. 2016;34: 1921-32.

164

Kronish IM, Woodward M, Sergie Z, et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011;123:1611-21.

165

Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens. 2017;35:2150-60.

166

Ishani A, Cushman WC, Leatherman SM, et al. Chlorthalidone vs. Hydrochlorothiazide for hypertension — cardiovascular events. N Engl J Med. 2022;387:2401-10.

167

Olde Engberink RH, Frenkel WJ, van den Bogaard B, et al. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension. 2015;65(5):1033-40. doi:10.1161/HYPERTENSIONAHA.114.05122.

168

Roush GC, Messerli FH. Chlorthalidone versus hydrochlorothiazide: major cardiovascular events, blood pressure, left ventricular mass, and adverse effects. J Hypertens. 2021;39(6):1254-60. doi:10.1097/HJH.0000000000002771.

169

Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens. 2008;26:819-24.

170

Brown MJ, Williams B, Morant SV, et al. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydro- chlorothiazide on glucose tolerance and blood pressure (PATHWAY-3):, a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2016;4:136-47.

171

Cushman WC, Ford CE, Cutler JA, et al., ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-404.

172

Palmer BF. Metabolic complications associated with use of diuretics. Semin Nephrol. 2011;31(6):542-52. doi:10.1016/j.semnephrol.2011.09.009.

173

Rimoldi SF, Messerli FH, Chavez P, Stefanini GG, Scherrer U. Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: a meta-analysis. J Clin Hypertens (Greenwich). 2015;17(3):193-9. doi:10.1111/jch.12462.

174

Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290-300. doi:10.1016/j.amjmed.2008.09.038.

175

Kang S, Wu YF, An N, Ren M. A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril-indapamide combination as first-line treatment of hypertension. Clin Ther. 2004;26(2):257-70. doi:10.1016/s0149-2918(04)90024-0.

176

Kizilirmak P, Berktas M, Uresin Y, Yildiz OB. The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013;15(3):193- 200. doi:10.1111/jch.12040.

177

Salam A, Atkins ER, Hsu B, et al. Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy: a systematic review and meta-analysis of randomized controlled trials. Journal of hypertension. 2019;37(8):1567-73.

178

Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021;385:2507-19.

179

Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375(9718):906-15. doi:10.1016/S0140-6736(10)60235-8.

180

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs — overview and meta-analyses. J Hypertens. 2015;33:195-211.

181

Schmieder RE, Wagner F, Mayr M, et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J. 2017;38(44):3308-17. doi:10.1093/eurheartj/ehx525.

182

Williams B, Cockcroft JR, Kario K, et al. Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study. Hypertension. 2017;69(3):411-20. doi:10.1161/HYPERTENSIONAHA.116.08556.

183

Izzo JL, Zappe DH, Jia Y, et al. Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study. Cardiovasc Pharmacol. 2017;69:374-81.

184

Jackson AM, Jhund SP, Anand AS, et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Euro Heart J. 2021;42:3741-52.

185

Geng Q, Yan R, Wang Z, Hou F. Effects of LCZ696 (Sacubitril/Valsartan) on Blood Pressure in Patients with Hypertension: A Meta-Analysis of Randomized Controlled Trials. Cardiology. 2020;145(9):589-598. doi:10.1159/000507327.

186

Li Q, Li L, Wang F, et al. Effect and safety of LCZ696 in the treatment of hypertension: A meta-analysis of 9 RCT studies. Medicine (Baltimore). 2019;98(28):e16093. doi:10.1097/MD.0000000000016093

187

Zhao Y, Yu H, Zhao X, et al. The Effects of LCZ696 in Patients With Hypertension Compared With Angiotensin Receptor Blockers: A Meta-Analysis of Randomized Controlled Trials. JCardiovasc Pharmacol Ther. 2017;22(5):447-57. doi:10.1177/1074248417693379.

188

Wang JG, Yukisada K, Sibulo A Jr, et al. Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy. J Hypertens. 2017;35(4):877-85. doi:10.1097/HJH.0000000000001219.

189

Solomon SD, Vaduganathan M, L Claggett B, et al. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020;141(5):352-61. doi:10.1161/CIRCULATIONAHA.119.044586.

190

McMurray JJ, Packer M, Desai AS, et al.; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077.

191

Böhm M, Young R, Jhund PS, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017;38(15):1132-43. doi:10.1093/eurheartj/ehw570.

192

Чазова И.Е., Мычка В.Б. Новые возможности в лечении больных с метаболическим синдромом: результаты исследования ALMAZ. Системные гипертензии. 2006;2:14-7.

Chazova IE, Mychka VB. New possibilities in the treatment of patients with metabolic syndrome: the results of the ALMAZ study. Systemic Hypertension. 2006;(2):14-7. (In Russ.)

193

Chazova I, Schlaich MP. Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. Int J Hypertens. 2013;2013:541689. doi:10.1155/2013/541689.

194

Rayner B. Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE? Curr Med Res Opin. 2004;20(3):359-67. doi:10.1185/030079904125002991.

195

Prichard BNC, Hughes PR, Jäger CA, et al. Dose relation of blood pressure reduction with moxonidine: findings from three placebo-and active-controlled randomized studies. Journal of Clinical and Basic Cardiology. 2003;6(1-4):49-51.

196

Williams B, MacDonald TM, Morant S, et al. British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2):, a randomised, doubleblind, crossover trial. Lancet. 2015;386:2059-68.

197

Chapman N, Chang CL, Dahlöf B, et al.; ASCOT Investigators. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation. 2008;118(1):42-8. doi:10.1161/CIRCULATIONAHA.107.737957.

198

Chernova I, Krishnan N. Resistant Hypertension Updated Guidelines. Curr Cardiol Rep. 2019;21(10):117. doi:10.1007/s11886-019-1209-6.

199

Böhm M, Kario K, Kandzari DE, et al.; SPYRAL HTN-OFF MED Pivotal Investigators. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444-51. doi:10.1016/S0140-6736(20)30554-7.

200

Azizi M, Schmieder RE, Mahfoud F, et al.; RADIANCE-HTN Investigators. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335-45. doi:10.1016/S0140-6736(18)31082-1. Erratum in: Lancet. 2018;392(10150):820. doi:10.1016/S0140-6736(18)32058-0.

201

Azizi M, Sanghvi K, Saxena M, et al.; RADIANCE-HTN investigators. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCEHTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397(10293):2476-86. doi:10.1016/S0140-6736(21)00788-1.

202

Kandzari DE, Bohm M, Mahfoud F, et al., SPYRAL HTN-ON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391:2346-55.

203

Kario K, Mahfoud F, Kandzari DE, et al. Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial. Hypertens Res. 2023;46(1):280-8. doi:10.1038/s41440-022-01042-8.

204

Biffi A, Dell’Oro R, Quarti-Trevano F, et al. Effects of renal denervation on sympathetic nerve traffic and correlates in drug-resistant and uncontrolled hypertension: a systematic review and meta-analysis. Hypertension. 2023;80:659-67.

205

DiBona GF. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005;289:R633-R641.

206

Narkiewicz K, Ratcliffe LE, Hart EC, et al. Unilateral carotid body resection in resistant hypertension: a safety and feasibility trial. JACC Basic Transl Sci. 2016;1:313-24.

207

Mahfoud F, Bohm M, Azizi M, et al. Proceedings from the European Clinical Consensus Conference for Renal Denervation: considerations on future clinical trial design. Eur Heart J. 2015;36:2219-27.

208

Kirtane AJ, Sharp ASP, Mahfoud F, et al., RADIANCE Investigators and Collaborators. Patient-level pooled analysis of ultrasound renal denervation in the sham-controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials. JAMA Cardiol. 2023;8:464.

209

Townsend RR, Walton A, Hettrick DA, et al. Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. EuroIntervention. 2020;16:89-96.

210

Lauder L, Azizi M, Kirtane AJ, et al. Device-based therapies for arterial hypertension. Nat Rev Cardiol. 2020;17:614-28.

211

Sarafidis PA, Lazaridis AA, Ruiz-Hurtado G, Ruilope LM. Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. Nat Rev Endocrinol. 2017;13(6):365-74. doi:10.1038/nrendo.2016.209.

212

Patel A; ADVANCE Collaborative Group; MacMahon S, Chalmers J, Neal B, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829-40. doi:10.1016/S0140-6736(07)61303-8.

213

Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 — Should blood pressure management differ in hypertensive patients with and without diabetes mellitus?, Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922-44.

214

Kario K, Tomitani N, Kanegae H, et al. Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication TechnologyBased Nocturnal Home Blood Pressure Monitoring — The NOCTURNE Study. Circ J. 2017;81(7):948-57. doi:10.1253/circj.CJ-17-0109.

215

Tsai WC, Wu HY, Peng YS, et al. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med. 2017;177:792-9.

216

SPRINT Research Group. A randomized trial of intensive versus standard blood pressure control. New England Journal of Medicine. 2015;373(22):2103-116.

217

Cheung AK, Rahman M, Reboussin DM, et al. Effects of intensive BP control in CKD. J Am Soc Nephrol. 2017;28:2812-23.

218

Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87.

219

Papademetriou V, Zaheer M, Doumas M, et al. Cardiovascular Outcomes in Action to Control Cardiovascular Risk in Diabetes: Impact of Blood Pressure Level and Presence of Kidney Disease. American Journal of Nephrology. 2016;43(4):271-80.

220

Blood Pressure Lowering Treatment Trialists’ Collaboration; Ninomiya T, Perkovic V, Turnbull F, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ. 2013;347:f5680. doi:10.1136/bmj.f5680.

221

Beddhu S, Chertow GM, Greene T, et al. Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus:, reconciling results from ACCORD and SPRINT. J Am Heart Assoc. 2018;7:e009326.

222

Tsujimoto T, Kajio H. Benefits of Intensive blood pressure treatment in patients with type 2 diabetes mellitus receiving standard but not intensive glycemic control. Hypertension. 2018;72:323-30.

223

Aggarwal R, Petrie, Bala W, et al. Mortality outcomes with intensive blood pressure targets in chronic kidney disease patients. Hypertension. 2019;73:1275-82.

224

Jafar TH, Stark PC, Schmid CH, et al. AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139:244-25.

225

Deng X, Li D, Tang Q, Chen Y. ACEI and ARB Lower the Incidence of End-Stage Renal Disease among Patients with Diabetic Nephropathy: A Meta-analysis. Comput Math Methods Med. 2022;2022:6962654. doi:10.1155/2022/6962654.

226

Zhang Y, He D, Zhang W, et al. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials. Drugs. 2020;80(8):797-811. doi:10.1007/s40265-020-01290-3.

227

Xie X, Liu Y, Perkovic V et al. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. Am J Kidney Dis. 2016;67(5):728-41. doi:10.1053/j.ajkd.2015.10.011.

228

Huang R, Feng Y, Wang Y, et al. Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis. PLoS One. 2017;12(1):e0168582. doi:10.1371/journal.pone.0168582.

229

Cho M, Choi CY, Choi YJ, Rhie SJ. Clinical outcomes of renin angiotensin system inhibitor-based dual antihypertensive regimens in chronic kidney disease: a network metaanalysis. Sci Rep. 2023;13(1):5727. doi:10.1038/s41598-023-32266-4.

230

Agarwal R, Sinha AD, Tu W. Chlorthalidone for resistant hypertension in advanced chronic kidney disease. Circulation. 2022;146:718-20.

231

Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-46. doi:10.1056/NEJMoa2024816.

232

Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(24):2301-2. doi:10.1056/NEJMc2301923.

233

Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474-84.

234

Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383:2219-29.

235

Brunstrom M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and metaanalysis. JAMA Intern Med. 2018;178:28-36.

236

Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435-43.

237

Vidal-Petiot E, Ford I, Greenlaw N, et al.; CLARIFY Investigators. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet. 2016;388(10056):2142-52. doi:10.1016/S0140-6736(16)31326-5.

238

Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.

239

Manolis AJ, Boden WE, Collins P, et al. State of the art approach to managing angina and ischemia: tailoring treatment to the evidence. Eur J Intern Med. 2021;92:40-7.

240

Bangalore S, Makani H, Radford M, et al. Clinical outcomes with b-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med. 2014;127:939-53.

241

Bangalore S, Fakheri R, Wandel S, et al. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and metaanalysis of randomized trials. BMJ. 2017;356:j4. doi:10.1136/bmj.j4.

242

Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009;54:1084-91.

243

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure — meta-analyses of randomized trials. J Hypertens. 2016;34:373-84.

244

Dahlöf B, Devereux RB, Kjeldsen SE, et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. doi:10.1016/S0140-6736(02)08089-3.

245

Authors/Task Force Members; McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24(1):4-131. doi:10.1002/ejhf.2333.

246

Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/ HFSA Guideline for the Management of Heart Failure. J Card Fail. 2022;28(5):e1-e167. doi:10.1016/j.cardfail.2022.02.010.

247

Zhang H, Huang T, Shen W, et al. Efficacy and safety of sacubitril-valsartan in heart failure: a meta-analysis of randomized controlled trials. ESC Heart Fail. 2020;7(6):3841-50. doi:10.1002/ehf2.12974.

248

Cleophas TJ, Zwinderman AH. Beta-blockers and heart failure: meta-analysis of mortality trials. Int J Clin Pharmacol Ther. 2001;39(9):383-8. doi:10.5414/cpp39383.

249

Berbenetz NM, Mrkobrada M. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis. BMC Cardiovasc Disord. 2016;16(1):246. doi:10.1186/s12872-016-0425-x.

250

Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013;346:f55. doi:10.1136/bmj.f55.

251

Zannad F, McMurray JJ, Krum H et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. doi:10.1056/NEJMoa1009492.

252

Burnett H, Earley A, Voors AA, et al. Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis. Circ Heart Fail. 2017;10(1):e003529. doi:10.1161/CIRCHEARTFAILURE.116.003529.

253

Shah RV, Desai AS, Givertz MM. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. J Card Fail. 2010;16(3):260-7. doi:10.1016/j.cardfail.2009.11.007.

254

Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335(15):1107-14.

255

Packer M, Carson P, Elkayam U, et al.; PRAISE-2 Study Group. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). JACC Heart Fail. 2013;1(4):308-14. doi:10.1016/j.jchf.2013.04.004.

256

Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem, Postinfarction Research Group. Circulation. 1991;83:52-60.

257

Physicians Desk Reference. 47th ed. Montvale. NJ: Medical Economics Company, 1993: 2250.

258

Hansen JF. Treatment with verapamil after an acute myocardial infarction. Review of the Danish studies on verapamil in myocardial infarction (DAVIT I and II). Drugs. 1991;42 Suppl 2:43-53. doi:10.2165/00003495-199100422-00008.

259

Cohn JN, Pfeffer MA, Rouleau J, et al. MOXCON Investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5:659-67.

260

ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA. 2000;283:1967-75.

261

Dorszewski A, Göhmann E, Dorszéwski B, et al. Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial:, results of a placebo-controlled, double-blind study. J Card Fail. 1997;3:91-6.

262

Bayliss J, Norell MS, Canepa-Anson R, et al. Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin. Br Med J (Clin Res Ed). 1985;290:1861-5.

263

Faris R, Flather M, Purcell H, et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomized controlled trials. Int J Cardiol. 2002;82:149-58.

264

Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure.Cochrane Database Syst Rev. 2012;2:CD003838.

265

Mc Causland FR, Lefkowitz MP, Claggett B, et al. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation. 2020;142(13):1236-5. doi:10.1161/CIRCULATIONAHA.120.0.

266

Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis, of double-blind randomized trials. Eur Heart J. 2018;39:26-35.

267

Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across, the entire ejection fraction spectrum. Eur J Heart Fail. 2018;20:1230-9.

268

Solomon SD, Claggett B, Lewis EF, et al.; TOPCAT Investigators. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart, failure with preserved ejection fraction. Eur Heart J. 2016; 37:455-62.

269

Solomon SD, McMurray JJV, Claggett B, et al; DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-98. doi:10.1056/NEJMoa2206286.

270

Anker SD, Butler J, Packer M. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. Reply. N Engl J Med. 2022;386(21):e57. doi:10.1056/NEJMc2118470.

271

Lin Y, Cai Z, Yuan J, et al. Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials. Cardiovasc Diabetol. 2022;21(1):237. doi:10.1186/s12933-022-01679-2.

272

Cleland JGF, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-45.

273

Yusuf S, Pfeffer MA, Swedberg K, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777-81. doi:10.1016/S0140-6736(03)14285-7.

274

Myhre PL, Vaduganathan M, Claggett BL, et al. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. JAMA Cardiol. 2018;3(10):1000-5. doi:10.1001/jamacardio.2018.2568.

275

Martin N, Manoharan K, Thomas J, et al. Beta-blockers and inhibitors of the reninangiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev. 2018;6:CD012721.

276

Hernandez AF, Hammill BG, O’Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with, Heart Failure) Registry. J Am Coll Cardiol. 2009;53(2):184-92.

277

Azizova AG, Ovchinnikov AG, Blankova ZN, Ageev FT. In patients with elevated LV filling pressure loop diuretics improve severity of heart failure and diastolic dysfunction, but torasemide does it somewhat better than furosemide. Eur J Heart Fail. 2011;10 (Suppl 2):S186.

278

Adamson PB, Abraham WT, Bourge RC, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7(6):935-44.

279

Cardoso R, Graffunder FP, Ternes CMP, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. EClinicalMedicine. 2021;36:100933. doi:10.1016/j.eclinm.2021.100933.

280

Pitt B, Pfeffer MA, Assmann SF, et al.; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-92. doi:10.1056/NEJMoa1313731.

281

Soliman EZ, Ambrosius WT, Cushman WC, et al.; SPRINT Research Study Group. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial). Circulation. 2017;136(5):440-50. doi:10.1161/CIRCULATIONAHA.117.028441. Erratum in: Circulation. 2017;136(5):e136. doi:10.1161/CIR.0000000000000528.

282

Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115(1):41-6. doi:10.1016/s0002-9343(03)00158-x.

283

Dahlöf B, Kjell P, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens. 1992;5(2):95-110. doi:10.1093/ajh/5.2.95.

284

Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю. и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. doi:10.15829/1560-4071-2021-4594.

Arakelyan MG, Bockeria LA, Vasilieva EYu, et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021;26(7):4594. (In Russ.) doi:10.15829/1560-4071-2021-4594.

285

Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7):492-501. doi:10.7326/0003-4819-131-7-199910050-00003.

286

Arima H, Chalmers J, Woodward M, et al. PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens. 2006;24:1201-8.

287

Rodriguez-Luna D, Pineiro S, Rubiera M, et al. Impact of blood pressure changes and courseon hematoma growth in acute intracerebral hemorrhage. Eur J Neurol. 2013;20:1277-83.

288

Sakamoto Y, Koga M, Yamagami H, et al. Systolic blood pressure afterintravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the stroke acute management with urgent risk-factorassessment and improvement, intracerebral hemorrhage study. Stroke. 2013;44:1846-51.

289

Anderson CS, Heeley E, Huang Y, et al. INTERACT2Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368: 2355-65.

290

Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375:1033-43.

291

Tsivgoulis G, Katsanos AH, Butcher KS, et al. Intensive blood pressure reduction in acute intracerebral hemorrhage: a meta-analysis. Neurology. 2014;83:1523-9.

292

Moullaali TJ, Wang X, Martin RH, et al. Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data. Lancet Neurol. 2019;18(9):857-64.

293

Steiner T, Al-Shahi Salman R, Beer R, et al.; European Stroke Organisation. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke. 2014;9(7):840-55. doi:10.1111/ijs.12309.

294

Hemphill JC 3rd, Greenberg SM, Anderson CS, et al.; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46(7):2032-60. doi:10.1161/STR.0000000000000069.

295

Powers WJ, Rabinstein AA, Ackerson T, et al.; American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46-e110. doi:10.1161/STR.0000000000000158. Erratum in: Stroke. 2018;49(3):e138. doi:10.1161/STR.0000000000000163. Erratum in: Stroke. 2018;49(6):e233-e234. doi:10.1161/STR.0000000000000172.

296

Lee M, Ovbiagele B, Hong KS, et al. Effectof blood pressure lowering in early ischemic stroke: meta-analysis. Stroke. 2015;46:1883-9.

297

Zhao R, Liu FD, Wang S, et al. Blood pressure reduction in the acute phase of an ischemic stroke does not improve short- or long-term dependency or mortality: a meta-analysis of current literature. Medicine(Baltimore). 2015;94:e896.

298

Ahmed N, Wahlgren N, Brainin M, et al. Relationship of blood pressure, antihypertensive therapy, and outcome inischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International, StrokeThrombolysis Register (SITS-ISTR). Stroke. 2009;40:2442-9.

299

Wu W, Huo X, Zhao X, et al. Relationship between blood pressure and outcomes in acute ischemic stroke patients administered lytic medication in the TIMS-China Study. PLoS One 2016;11:e0144260.

300

White CL, Szychowski JM, Pergola PE, et al. Secondary Prevention of Small Subcortical Strokes Study Investigators. Can blood pressure be lowered safely in older adults with lacunar stroke? The Secondary Prevention of Small Subcortical Strokes study, experience. J Am Geriatr Soc. 2015;63:722-9.

301

PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressurelowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-41. doi:10.1016/S0140-6736(01)06178-5. Erratum in: Lancet. 2001;358(9292):1556. Erratum in: Lancet. 2002;359(9323):2120.

302

Lu Z, Chen Y, Li L, et al. Combination therapy of renin-angiotensin system inhibitors plus calcium channel blockers versus other two-drug combinations for hypertension: a systematic review and meta-analysis. J Hum Hypertens. 2017;31(1):1-13. doi:10.1038/jhh.2015.125.

303

Chi C, Tai C, Bai B, et al. Angiotensin System Blockade Combined With Calcium Channel Blockers Is Superior to Other Combinations in Cardiovascular Protection With Similar Blood Pressure Reduction: A Meta-Analysis in 20,451 Hypertensive Patients. J Clin Hypertens (Greenwich). 2016;18(8):801-8. doi:10.1111/jch.12771.

304

Wang JG, Staessen JA, Li Y, et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke. 2006;37(7):1933-40. doi:10.1161/01.STR.0000227223.90239.13.

305

Lane DA, Lip GY. Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev. 2013;(12):CD003075. doi:10.1002/14651858.CD003075.pub3.

306

Zanchetti A, Hennig M, Hollweck R, et al. Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation. 2009;120(12):1084-90. doi:10.1161/CIRCULATIONAHA.108.773119.

307

Zanchetti A, Crepaldi G, Bond MG, et al. PHYLLIS Investigators. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis:, principal results of PHYLLIS — a randomized double-blind trial. Stroke. 2004;35:2807-12.

308

Myou S, Fujimura M, Kamio Y, et al. Effect of losartan, a type 1 angiotensin II receptor antagonist, on bronchial hyperresponsiveness to methacholine in patients with bronchial asthma. Am J Respir Crit Care Med. 2000;162:40-4.

309

Chiu KY, Li JG, Lin Y. Calcium channel blockers for lung function improvement in asthma: A systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2017;119(6):518- 523.e3.

310

Mortensen EM, Copeland LA, Pugh MJV, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.

311

Tanaka H, Teramoto S, Oashi K, et al. Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. Circulation. 2001;104(3):281-5.

312

Huang KY, Tseng PT, Wu YC, et al. Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials. Scientific reports. 2021;11(1):452.

313

Bennett M, Chang CL, Tatley M, Savage R, Hancox RJ. The safety of cardioselective β1-blockers in asthma: literature review and search of global pharmacovigilance safety reports. ERJ Open Res. 2021;7(1):00801-2020. doi:10.1183/23120541.00801-2020.

314

Song WJ, Niimi A. Angiotensin-Converting Enzyme Inhibitors, Asthma, and Cough: Relighting the Torch. J Allergy Clin Immunol Pract. 2021;9(9):3440-41. doi:10.1016/j.jaip.2021.07.002.

315

Finks SW, Rumbak MJ, Self TH. Treating Hypertension in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2020;382:353-63.

316

Yang YL, Xiang ZJ, Yang JH, et al. Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2020;41(46):4415-22. doi:10.1093/eurheartj/ehaa793.

317

Dos Santos NC, Camelier AA, Menezes AK, et al. Effects of the Use of Beta-Blockers on Chronic Obstructive Pulmonary Disease Associated with Cardiovascular Comorbities: Systematic Review and Meta-analysis. Tuberc Respir Dis (Seoul). 2024;87(3):261-81. doi:10.4046/trd.2024.0013.

318

Fava C, Dorigoni S, Dalle Vedove F, et al. Effect of CPAP on blood pressure in patients with OSA/hypopnea a systematic review and meta-analysis. Chest. 2014;145(4):762-71. doi:10.1378/chest.13-1115.

319

Labarca G, Schmidt A, Dreyse J, et al. Efficacy of continuous positive airway pressure (CPAP) in patients with obstructive sleep apnea (OSA) and resistant hypertension (RH): Systematic review and meta-analysis. Sleep Med Rev. 2021;58:101446. doi:10.1016/j.smrv.2021.101446.

320

Сукмарова З.Н., Литвин А.Ю., Чазова И.Е., Рогоза А.Н. Эффективность комплексной медикаментозной и CPAP-терапии у пациентов с артериальной гипертонией 2-3-й степени и тяжелой степенью синдрома обструктивного апноэ во время сна. Системные гипертензии, 2011:8(1):40.

Sukmarova ZN, Litvin AYu, Chazova IE, Rogoza AN. Effectiveness of complex drug and CPAP therapy in patients with arterial hypertension of the 2nd-3rd degree and severe obstructive sleep apnea syndrome. Systemic Hypertension. 2011;8(1):40-3. (In Russ.)

321

Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management:The Joint Task Force on non-cardiac surgery: cardiovascular assessment andmanagement of the European Society of Cardiology, (ESC) and the EuropeanSociety of Anaesthesiology (ESA). Eur Heart J. 2014;35:2383-431.

322

Futier E, Lefrant JY, Guinot PG, et al. Effect of individualized vs standardblood pressure management strategies on postoperative organ dysfunctionamong high-risk patients undergoing major surgery: a randomized clinical trial. JAMA. 2017;318:1346-57.

323

London MJ, Hur K, Schwartz GG, Henderson WG. Association of perioperative betablockade with mortality and cardiovascular morbidity following major non-cardiac surgery. JAMA. 2013;309:1704-13.

324

Andersson C, Merie C, Jorgensen M, et al. Association of beta-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwidecohort study. JAMA Intern Med. 2014;174:336-44.

325

Lederballe Pedersen O, Mikkelsen E, Lanng Nielsen J, Christensen NJ. Abrupt withdrawal of beta-blocking agents in patients with arterial hypertension. Effect on blood pressure, heart rate and plasma catecholamines and prolactin. Eur J Clin Pharmacol. 1979;15(3):215-7. doi:10.1007/BF00563108.

326

Gupta P, Patel P, Strauch B, et al. Biochemical screening for nonadherence is associated with blood pressure reduction and improvement in adherence. Hypertension. 2017;70:1042-8.

327

Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens. 2015; 28:355-61.

328

Kario K, Hoshide S, Narita K, et al. Cardiovascular prognosis in drug-resistant hypertension stratified by 24-hour ambulatory blood pressure: the JAMP Study. Hypertension. 2021;78:1781-90.

329

Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens. 2001;19:2063-70.

330

Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistanthypertension: results from a randomized trial. Hypertension. 2009;54:475-81.

331

Liu L, Xu B, Ju Y. Addition of spironolactone in patients with resistant hypertension: a metaanalysis of randomized controlled trials. Clin Exp Hypertens. 2017;39:257-63.

332

Wang C, Xiong B, Huang J. Efficacy and safety of spironolactone in patients with re - sistant hypertension: a meta-analysis of randomised controlled trials. Heart Lung Circ. 2016;25:1021-30.

333

Chen C, Zhu XY, Li D, et al. Clinical efficacy and safety of spironolactone in patients with resistant hypertension: a systematic review and meta-analysis. Medicine (Baltimore). 2020;99:e21694.

334

Krieger EM, Drager LF, Giorgi DMA, et al., ReHOT Investigators. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT Randomized Study (Resistant Hypertension Optimal Treatment). Hypertension. 2018;71:681-90.

335

Williams B, MacDonald TM, Morant SV, et al., British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6:464-75.

336

Desai R, Park H, Brown JD, et al Comparative safety and effectiveness of aldosterone antagonists versus beta-blockers as fourth agents in patients with apparent resistant hypertension. Hypertension. 2022;79:2305-15.

337

Sinnott SJ, Tomlinson LA, Root AA, et al. Comparative effectiveness of fourth-line antihypertensive agents in resistant hypertension: A systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24(3):228-38. doi:10.1177/2047487316675194.

338

Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014;4:CD007004.

339

Loutradis C, Sarafidis P. Hypertension in patients with advanced chronic kidney disease. In: Mancia G, Grassi G, Tsioufis K, Dominiczak A, Rosei EA, editors. Manual of hypertension of the European Society of Hypertension. Boca Raton: CRC Press; 2019. 674 p. ISBN: 9780429583346.

340

Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opin Pharmacother. 2014;15:605-21.

341

Azizi M, Saxena M, Wang Y, et al.; RADIANCE II Investigators and Collaborators. Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial. JAMA. 2023;329(8):651-61. doi:10.1001/jama.2023.0713. Erratum in: JAMA. 2023;329(22):1989. doi:10.1001/jama.2023.8136.

342

Hu X, Fan J, Chen S, et al. The role of continuous positive airway pressure in blood pressure control for patients with obstructive sleep apnea and hypertension: a meta-analysis of randomized controlled trials. J Clin Hypertens (Greenwich). 2015;17:215-22.

343

Martinez-Garcia MA, Pengo MF. Clinical phenotype of resistant hypertension responders to continuous positive airway pressure treatment: results from the HIPARCO Randomized Clinical Trial. Hypertension. 2021;78:559-61.

344

Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2022;399:259-69.

345

Maringwa J, Sardu ML, Hang Y, et al. Characterizing effects of antidiabetic drugs on heart rate, systolic and diastolic blood pressure. Clin Pharmacol Ther. 2021;109:1583-92.

346

Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20:189.

347

Schiavon CA, Ikeoka D, Santucci EV, et al. Effects of bariatric surgery versus medical therapy on the 24-hour ambulatory blood pressure and the prevalence of resistant hypertension. Hypertension. 2019;73:571-5.

348

Georgianos PI, Agarwal R. Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide. Diabetes Care. 2019;42:693-700.

349

Ruilope L.M. et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin:a randomised, double-blind, placebocontrolled, active comparator study. Lancet. 2010;375:1255-66.

350

Huang Y, Huang W, Mai W, et al. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. J Hypertens. 2017;35:677-88.

351

Briasoulis A, Androulakis E, Palla M, et al. White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens. 2016;34:593-9.

352

Cuspidi C, Rescaldani M, Tadic M, et al. White-coat hypertension, as defined by ambulatory blood pressure monitoring, and subclinical cardiac organ damage: a meta-analysis. J Hypertens. 2015;33:24-32.

353

Mancia G, Bombelli M, Facchetti R, et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J Hypertens. 2009;27:1672-8.

354

Tientcheu D, Ayers C, Das SR, et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J Am Coll Cardiol. 2015;66:2159-69.

355

Stergiou GS, Asayama K, Thijs L, et al., International Database on HOme blood pressure in relation to Cardiovascular Outcome (IDHOCO) Investigators. Prognosis of white-coat and masked hypertension: International Database of HOme blood pressure in relation to Cardiovascular Outcome. Hypertension. 2014;63(4):675-82. doi:10.1161/HYPERTENSIONAHA.113.02741.

356

Thakkar HV, Pope A, Anpalahan M. Masked Hypertension: A Systematic Review. Heart Lung Circ. 2020;29(1):102-11. doi:10.1016/j.hlc.2019.08.006.

357

Palla M, Saber H, Konda S, Briasoulis A. Masked hypertension and cardiovascular outcomes: an updated systematic review and meta-analysis. Integr Blood Press Control. 2018;11:11-24.

358

Zhang DY, Guo QH, An DW, et al. A comparative meta-analysis of prospective observational studies on masked hypertension and masked uncontrolled hypertension defined by ambulatory and home blood pressure. J Hypertens. 2019;37:1775-85.

359

Egan BM, Li J, Hutchison FN, Ferdinand KC. Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals. Circulation. 2014;130(19):1692-9.

360

Liu X, Rodriguez CJ, Wang K. Prevalence and trends of isolated systolic hypertension among untreated adults in the United States. J Am Soc Hypertens. 2015;9(3):197-205.

361

Bavishi C, Goel S, Messerli FH. Isolated Systolic Hypertension: An Update After SPRINT Am J Med. 2016;129(12):1251-8.

362

Ekundayo OJ, Allman RM, Sanders PW, et al. Isolated systolic hypertension and incident heart failure in older adults: a propensity-matched study. Hypertension. 2009;53(3): 458-65.

363

Li Y, Wei FF, Thijs L, et al. Ambulatory hypertension subtypes and 24-hour systolic and diastolic blood pressure as distinct outcome predictors in 8341 untreated people recruited from 12 populations. Circulation. 2014;130(6):466-74.

364

SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA. 1991;265(24):3255-64.

365

Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst-Eur) trial investigators. Lancet. 1997;350(9080):757-64.

366

Wang JG, Staessen JA, Gong L, et al. Chinese trial on isolated systolic hypertension in the elderly. Systolic hypertension in China (Syst-China) collaborative group. Arch Intern Med. 2000;160(2):211-20.

367

Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, doubleblind, placebo-controlled study. Hypertension. 2014;63(4):698-705. doi:10.1161/HYPERTENSIONAHA.113.02002.

368

Perry HM Jr, Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 2000;284:465-71.

369

Ogihara T, Saruta T, Rakugi H, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension. 2010;56:196-202.

370

Sobieraj P, Lewandowski J, Sin ski M, Gaciong Z. Low on-treatment diastolic blood pressure and cardiovascular outcome: a posthoc analysis using NHLBI SPRINT Research Materials. Sci Rep. 2019;9:13070.

371

Franklin SS, Chow VH, Mori AD, Wong ND. The significance of low DBP in US adults with isolated systolic hypertension. J Hypertens. 2011;29:1101-8.

372

O’Rourke MF, Adji A. Guidelines on guidelines: focus on isolated systolic hypertension in youth. J Hypertens. 2013;31:649-54.

373

Yano Y, Stamler J, Garside DB, et al. Isolated systolic hypertension in young and middleaged adults and 31-year risk for cardiovascular mortality: the Chicago Heart Association Detection Project in Industry study. JAmCollCardiol. 2015;65:327-35.

374

Yu S, Zhang Y. The association between isolated systolic or diastolic hypertension and cardiovascular risk. J Hypertens. 2021;39:1552-4.

375

Romero CA, Tabares AH, Orias M. Is isolated diastolic hypertension an important phenotype? Curr Cardiol Rep. 2021;23:177.

376

Xie K, Gao X, Bao L, et al. The different risk factors for isolated diastolic hypertension and isolated systolic hypertension: a national survey. BMC Public Health. 2021;21:1672.

377

Mahajan S, Zhang D, He S, et al.; China PEACE Collaborative Group §; China PEACE Collaborative Group. Prevalence, Awareness, and Treatment of Isolated Diastolic Hypertension: Insights From the China PEACE Million Persons Project. J Am Heart Assoc. 2019;8(19):e012954. doi:10.1161/JAHA.119.012954.

378

Jacobsen AP, Al Rifai M, Arps K, et al. A cohort study and meta-analysis of isolated diastolic hypertension: searching for a threshold to guide treatment. Eur Heart J. 2021;42:2119-29.

379

Li FR, He Y, Yang HL, et al. Isolated systolic and diastolic hypertension by the 2017 American College of Cardiology/American Heart Association guidelines and risk of cardiovascular disease: a large prospective cohort study. J Hypertens. 2021;39:1594-601.

380

Huang M, Long L, Tan L, et al. Isolated diastolic hypertension and risk of cardiovascular events: a systematic review and meta-analysis of cohort studies with 489,814 partici - pants. Front Cardiovasc Med. 2021;8:810105.

381

McEvoy JW, Yang WY, Thijs L, et al.; International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes (IDACO) Investigators. Isolated Diastolic Hypertension in the IDACO Study: An Age-Stratified Analysis Using 24-Hour Ambulatory Blood Pressure Measurements. Hypertension. 2021;78(5):1222-31. doi:10.1161/HYPERTENSIONAHA.121.17766.

382

Ogihara T, Saruta T, Rakugi H, et al.; COLM Investigators. Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial., Hypertens Res 2015;38:89-96.

383

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 — effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis., J Hypertens. 2018;36(8):1637-47. doi:10.1097/HJH.0000000000001777.

384

Corrao G, Mazzola P, Monzio Compagnoni M, et al. Antihypertensive medications, loop diuretics, and risk of hip fracturein the elderly: a population-based cohort study of 81,617 Italian patients newly treated between 2005 and 2009. Drugs Aging. 2015;32(11):927-36. doi:10.1007/s40266-015-0306-5.

385

Kjeldsen SE, Stenehjem A, Os I, et al. Treatment of high blood pressure in elderlyand octogenarians: European Society of Hypertension statement on blood pressure targets. Blood Press. 2016;25:333-6.

386

Aparicio LS, Thijs L, Boggia J, et al. Defining thresholds for home blood pressure monitoring in octogenarians.Hypertension (Dallas, Tex: 1979). 2015;66:865-873.

387

Zhang W, Zhang S, Deng Y, et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021;385:1268-79. doi:10.1056/NEJMoa2111437.

388

Ashworth DC, Maule SP, Stewart F, et al. Setting and techniques for monitoring blood pressure during pregnancy. Cochrane Database Syst Rev. 2020;8(8):CD012739.

389

Johnson S, Gordijn S, Damhuis S, et al; ISSHP. Diagnosis and Monitoring of White Coat Hypertension in Pregnancy: an ISSHP Consensus Delphi Procedure. Hypertension. 2022;79(5):993-1005.

390

Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5): 1122-31. doi:10.1097/01.AOG.0000437382.03963.88.

391

Tita AT, Szychowski JM, Andrews WW. Treatment for Mild Chronic Hypertension during Pregnancy. Reply. N Engl J Med. 2022;387(7):664. doi:10.1056/NEJMc2207889.

392

Magee LA, Singer J, von Dadelszen P, Group CS. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372:2367-8.

393

Easterling T, Mundle S, Bracken H, et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet. 2019;394(10203):1011-21. doi:10.1016/S0140-6736(19)31282-6.

394

Weitz C, Khouzami V, Maxwell K, Johnson JW. Treatment of hypertension in pregnancy with methyldopa: a randomized double blind study. Int J Gynaecol Obstet. 1987;25(1): 35-40. doi:10.1016/0020-7292(87)90181-0.

395

Garovic VD, Dechend R, Easterling T, et al; Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement From the American Heart Association. Hypertension. 2022;79(2):e21-e41. doi:10.1161/HYP.0000000000000208.

396

Комитет экспертов Российского кардиологического общества (РКО). Секция заболевания сердечно-сосудистой системы у беременных рекомендации по диагностике и лечению сердечно-сосудистых заболеваний при беременности 2018 новая редакция: июль 2018 года. Российский кардиологический журнал. 2018;(7):156-200. doi:10.15829/1560-4071-2018-7-156-200.

The committee of experts of the Russian Society of Cardiology (RSC). Section of cardiovascular diseases in pregnant women. National guidelines for diagnosis and treatment of cardiovascular diseases during pregnancy 2018. New revision: july, 2018. Russian Journal of Cardiology. 2018;(7):156-200. (In Russ.) doi:10.15829/1560-4071-2018-7-156-200.

397

Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Kardiol Pol. 2019;77(3):245-326. doi:10.5603/KP.2019.0049.

398

Cífková R. Hypertension in Pregnancy: A Diagnostic and Therapeutic Overview. High Blood Press Cardiovasc Prev. 2023;30(4):289-303.

399

Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:613-22.

400

Roberge S, Nicolaides K, Demers S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216(2):110-20.e6. doi:10.1016/j.ajog.2016.09.076.

401

Duley L, Meher S, Hunter KE, et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2019;2019(10):CD004659. doi:10.1002/14651858.CD004659.pub3.

402

Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2018;10(10): CD002252. doi:10.1002/14651858.CD002252.pub4.

403

Halpern DG, Weinberg CR, Pinnelas R, et al. Use of Medication for Cardiovascular Disease During Pregnancy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(4):457-76. doi:10.1016/j.jacc.2018.10.075.

404

Magee LA, Brown MA, Hall DR, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022;27:148-69. doi:10.1016/j.preghy.20.

405

Al Khalaf SY, O’Reilly ÉJ, Barrett PM, et al. Impact of chronic hypertension and antihypertensive treatment on adverse perinatal outcomes: systematic review and metaanalysis. J Am Heart Assoc. 2021;10(9):e018494. doi:10.1161/JAHA.120.018494.

406

Kayser A, Beck E, Hoeltzenbein M, et al. Neonatal effects of intrauterine metoprolol/bisoprolol exposure during the second and third trimester: a cohort study with two comparison groups. J Hypertens. 2020;38(2):354-61. doi:10.1097/HJH.0000000000002256.

407

Katsi V, Papakonstantinou IP, Papazachou O, Makris T, Tsioufis K. Beta-Blockers in Pregnancy: Clinical Update. Curr Hypertens Rep. 2023;25(2):13-24. doi:10.1007/s11906-023-01234-8.

408

Tuimala R, Punnonen R, Kauppila E. Clonidine in the treatment of hypertension during pregnancy. Ann Chir Gynaecol Suppl. 1985;197:47-50.

409

Williams B, Mancia G, Spiering W, et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Press. 2018;27(6):314-40. doi:10.1080/08037051.2018.1527177. Erratum in: Blood Press. 2019;28(1):74. doi:10.1080/08037051.2018.1557365.

410

Fu J, Tomlinson G, Feig DS. Increased risk of major congenital malformations in early pregnancy use of angiotensin-converting-enzyme inhibitors and angiotensin-receptorblockers: a meta-analysis. Diabetes Metab Res Rev. 2021;37(8):e3453. doi:10.1002/dmrr.3453.

411

Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354(23):2443-51. doi:10.1056/NEJMoa055202.

412

Society for Maternal-Fetal Medicine; Publications Committee. Electronic address: pubs@ smfm.org. Society for Maternal-Fetal Medicine Statement: Antihypertensive therapy for mild chronic hypertension in pregnancy-The Chronic Hypertension and Pregnancy trial. Am J Obstet Gynecol. 2022;227(2):B24-B27. doi:10.1016/j.ajog.2022.04.011.

413

Curtis KM, Mohllajee AP, Martins SL, Peterson HB. Combined oral contraceptive use among women with hypertension: a systematic review. Contraception. 2006;73(2): 179-88. doi:10.1016/j.contraception.2005.08.005.

414

Lubianca JN, Moreira LB, Gus M, Fuchs FD. Stopping oral contraceptives: an effective blood pressure-lowering intervention in women with hypertension. J Hum Hypertens. 2005;19:451-5.

415

Chasan-Taber L, Willett WC, Manson JE, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation. 1996;94:483-9.

416

Dong W, Colhoun HM, Poulter NR. Blood pressure in women using oral contraceptives: results from the Health Survey for England. 1994. J Hypertens. 1997;15:1063-8.

417

Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA. 2000;284:72-8.

418

La Torre A, Giupponi G, Duffy D, et al. Sexual dysfunction related to drugs: a critical review. Part IV: cardiovascular drugs.Pharmacopsychiatry. 2015;48:1-6.

419

Pickering TG, Shepherd AM, Puddey I, et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am J Hypertens. 2004;17(12 Pt 1):1135-42. doi:10.1016/j.amjhyper.2004.07.004.

420

Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep. 2007;9:320-8.

421

Hassen LJ, Lenihan DJ, Baliga RR. Hypertension in the Cardio-Oncology Clinic. Heart Fail Clin. 2019;15(4):487-95. doi:10.1016/j.hfc.2019.06.010.

422

van Dorst DCH, Dobbin SJH, Neves KB, et al. Hypertension and prohypertensive antineoplastic therapies in cancer patients. Circ Res. 2021;128:1040-61.

423

Kim CS, Han KD, Choi HS, et al. Association of hypertension and blood pressure with kidney cancer risk: a nationwide population-based cohort study. Hypertension. 2020;75:1439-46.

424

Alcala K, Mariosa D, Smith-Byrne K, et al. The relationship between blood pressure and risk of renal cell carcinoma. Int J Epidemiol. 2022;51:1317-27.

425

Weikert S, Boeing H, Pischon T, et al. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol. 2008;167:438-46.

426

Cohen JB, Brown NJ, Brown SA, et al. Cancer therapy-related hypertension: a scientific statement from the American Heart Association. Hypertension. 2023; 80:e46-e57.

427

Tlemsani C, Mir O, Boudou-Rouquette P, et al. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol. 2011;6:253-8.

428

Ferrara N, Adamis AP. Ten years of antivascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385-403.

429

Versmissen J, Mirabito Colafella KM, Koolen SLW, et al. Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension. Cardiovasc Res. 2019;115:904-14.

430

Webster K, Fishburn S, Maresh M, et al. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance. BMJ. 2019;366:l5119.

431

Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375:1457-67.

432

Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med. 2008;358:95-7.

433

Baek Moller N, Budolfsen C, Grimm D, et al. Drug-induced hypertension caused by multikinase inhibitors (sorafenib, sunitinib, lenvatinib and axitinib) in renal cell carcinoma treatment. Int J Mol Sci. 2019;20:4712.

434

Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and, and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022:ehac244. doi:10.1093/eurheartj/ehac244.

435

Campia U, Moslehi JJ, Amiri-Kordestani L, et al. Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association. Circulation. 2019;139:e579-e602.

436

Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 358:1129-36.

437

van Dorst DCH, van Doorn L, Mirabito Colafella KM, et al. Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic antitumour effects at the cost of increased cardiovascular risk? Clin Sci (Lond). 2021;135:1649-68.

438

щ438. Roviello G, Sigala S, Danesi R, et al. Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: a meta-analysis of published trials. Crit Rev Oncol Hematol. 2016;101:12-20.

439

Attard G, Reid AH, Auchus RJ, et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab. 2012;97:507-516.

440

Izzedine H, Cluzel P, Deray G. Renal radiation-induced arterial stenosis. Kidney Int. 2007;71(11):1188. doi:10.1038/sj.ki.5002137.

441

Biaggioni I, Shibao CA, Diedrich A, et al. Blood pressure management in afferent baroreflex failure: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;74:2939-47.

442

Weintraub NL, Jones WK, Manka D. Understanding radiation-induced vascular disease. J Am Coll Cardiol. 2010;55:1237-9.

443

Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102:596-604.

444

Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43:280-99.

445

Chang HM, Okwuosa TM, Scarabelli T, et al. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 2. J Am Coll Cardiol. 2017;70:2552-65.

446

Milan A, Puglisi E, Ferrari L, et al. Arterial hypertension and cancer. Int J Cancer. 2014;134:2269-77.

447

Penttilä P, Rautiola J, Poussa T, Peltola K, Bono P. Angiotensin inhibitors as treatment of sunitinib/pazopanib-induced hypertension in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2017;15:384-90.e3. doi:10.1016/j.clgc.2016.12.016.

448

Izzedine H, Derosa L, Le Teuff G, et al. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann Oncol. 2015;26:1128-33. doi:10.1093/annonc/mdv147.

449

McKay RR, Rodriguez GE, Lin X, et al. Angiotensin system inhibitors and survival outcomes in patients with meta- static renal cell carcinoma. Clin Cancer Res. 2015;21:2471-9. doi:10.1158/1078-0432.CCR-14-2.

450

Li XY, Sun JF, Hu SQ. The renin-angiotensin system blockers as adjunctive therapy for cancer: a meta-analysis of survival outcome. Eur Rev Med Pharmacol Sci. 2017;21(6):1375-83.

451

Steingart RM, Bakris GL, Chen HX, et al. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J. 2012;163:156-63.

452

Beavers CJ, Rodgers JE, Bagnola AJ, et al.; American Heart Association Clinical Pharmacology Committee and Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; and the Council on Peripheral Vascular Disease. Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association. Circulation. 2022;145(15):e811-e838. doi:10.1161/CIR.0000000000001056.

453

van Dorst DCH, Kabadayi S, Oomen-de Hoop E, et al. Treatment and implications of vascular endothelial growth factor inhibitor-induced blood pressure rise: a clinical cohort study. J Am Heart Assoc. 2023;12:e028050.

454

van Doorn L, Visser WJ, van Dorst DCH, et al. Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension. Br J Cancer. 2023;128: 354-62.

455

Gibson TM, Li Z, Green DM, et al. Blood pressure status in adult survivors of childhood cancer: a report from the St.Jude Lifetime Cohort Study. Cancer Epidemiol Biomarkers Prev. 2017;26:1705-13.

456

Cannon CP, Blazing MA, Giugliano RP, et al.; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25): 2387-97. doi:10.1056/NEJMoa1410489.

457

Cholesterol Treatment Trialists’ (CTT) Collaboration; Fulcher J, O’Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: metaanalysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397-405. doi:10.1016/S0140-6736(14)61368-4.

458

Sabatine MS, Giugliano RP, Keech AC, et al.; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-22. doi:10.1056/NEJMoa1615664.

459

Cholesterol Treatment Trialists’ (CTT) Collaborators; Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-90. doi:10.1016/S0140-6736(12)60367-5.

460

Vallejo-Vaz AJ, Ray KK, Ginsberg HN, et al. Associations between lower levels of lowdensity lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019;288:85-93. doi:10.1016/j.atherosclerosis.2019.07.008.

461

Yusuf S, Lonn E, Pais P, et al; HOPE-3 Investigators. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med. 2016;374(21):2032- 43. doi:10.1056/NEJMoa1600177.

462

Sever PS, Dahlof B, Poulter NR, et al. ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lowerthan- average cholesterol concentrations, in the Anglo-Scandinavian Cardiac, Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58.

463

Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532-61. doi:10.1016/S0140-6736(16)31357-5. Erratum in: Lancet. 2017;389(10069):602. doi:10.1016/S0140-6736(16)31468-4.

464

Bhatt DL, Steg PG, Miller M, et al., REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11-22.

465

Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324:2268-80.

466

Joseph P, Roshandel G, Gao P, et al; Polypill Trialists’ Collaboration. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021;398(10306):1133- 46. doi:10.1016/S0140-6736(21)01827-4.

467

Castellano JM, Pocock SJ, Bhatt DL, et al; SECURE Investigators. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387(11):967-77. doi:10.1056/NEJMoa2208275.

468

Coca A, Agabiti-Rosei E, Cifkova R, et al. The polypill in cardiovascular prevention: evidence, limitations and perspective — position paper of the European Society of Hypertension. J Hypertens. 2017;35:1546-53.

469

Lip GY, Felmeden DC, Dwivedi G. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev. 2011;2011(12):CD003186. doi:10.1002/14651858.CD003186.pub3.

470

Shantsila E, Kozieł-Siołkowska M, Lip GY. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev. 2022;7:CD003186. doi:10.1002/14651858.CD003186.pub4.

471

ASCEND Study Collaborative Group; Bowman L, Mafham M, Wallendszus K, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018;379(16):1529-39. doi:10.1056/NEJMoa1804988.

472

Seidu S, Kunutsor SK, Sesso HD, et al. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovasc Diabetol. 2019;18(1):70. doi:10.1186/s12933-019-0875-4.

473

Бойцов С.А., Погосова Н.В., Аншелес А.А. и др. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал. 2023;28(5):5452. doi:10.15829/1560-4071-2023-5452.

Boytsov SA, Pogosova NV, Ansheles AA, et al. Cardiovascular prevention 2022. Russian national guidelines. Russian Journal of Cardiology. 2023;28(5):5452. (In Russ.) doi:10.15829/1560-4071-2023-5452.

474

van den Born BH, Lip GYH, Brguljan-Hitij J, et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother. 2019;5(1):37-46. doi:10.1093/ehjcvp/pvy032. Erratum in: Eur Heart J Cardiovasc Pharmacother. 2019;5(1):46. doi:10.1093/ehjcvp/pvy040.

475

Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. 2000;356(9227):411-7. doi:10.1016/S0140-6736(00)02539-3.

476

Chester EM, Agamanolis DP, Banker BQ, Victor M. Hypertensive encephalopathy: a clinicopathologic study of 20 cases. Neurology. 1978;28(9 Pt 1):928-39. doi:10.1212/wnl.28.9.928.

477

van den Born BJ, Koopmans RP, Groeneveld JO, van Montfrans GA. Ethnic disparities in the incidence, presentation and complications of malignant hypertension. J Hypertens. 2006;24(11):2299-304. doi:10.1097/01.hjh.0000249710.21146.38.

478

Cremer A, Amraoui F, Lip GY, et al. From malignant hypertension to hypertensionMOD: a modern definition for an old but still dangerous emergency. J Hum Hypertens. 2016;30(8):463-6. doi:10.1038/jhh.2015.112.

479

Pinna G, Pascale C, Fornengo P, et al. Hospital admissions for hypertensive crisis in the emergency departments: a large multicenter Italian study. PLoS One. 2014;9(4):e93542. doi:10.1371/journal.pone.0093542.

480

van den Born BJ, Löwenberg EC, van der Hoeven NV, et al. Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. J Hypertens. 2011;29(5):922-7. doi:10.1097/HJH.0b013e328345023d.

481

Grassi D, O’Flaherty M, Pellizzari M, et al.; Group of Investigators of the REHASE Program. Hypertensive urgencies in the emergency department: evaluating blood pressure response to rest and to antihypertensive drugs with different profiles. J Clin Hypertens (Greenwich). 2008;10(9):662-7. doi:10.1111/j.1751-7176.2008.00001.x.

482

Perez MI, Musini VM. Pharmacological interventions for hypertensive emergencies: a Cochrane systematic review. J Hum Hypertens. 2008;22(9):596-607. doi:10.1038/jhh.2008.25.

483

Grossman A, Messerli FH, Grossman E. Drug induced hypertension--An unappreciated cause of secondary hypertension. Eur J Pharmacol. 2015;763(Pt A):15-22. doi:10.1016/j.ejphar.2015.06.027.

484

Cicero AFG, Grassi D, Tocci G, et al. Nutrients and Nutraceuticals for the Management of High Normal Blood Pressure: An Evidence-Based Consensus Document. High Blood Press Cardiovasc Prev. 2019;26(1):9-25. doi:10.1007/s40292-018-0296-6.

485

GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1345-422. doi:10.1016/S0140-6736(17)32366-8. Erratum in: Lancet. 2017;390(10104):1736. doi:10.1016/S0140-6736(17)32485-6. Erratum in: Lancet. 2017;390(10106):e38. doi:10.1016/S0140-6736(17)32649-1.

486

Solano López AL. Effectiveness of the Mindfulness-Based Stress Reduction Program on Blood Pressure: A Systematic Review of Literature. Worldviews Evid Based Nurs. 2018;15(5):344-52. doi:10.1111/wvn.12319.

487

Ambrosetti M, Abreu A, Corrà U, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. European Journal of Preventive Cardiology. 2020;28:460-95. doi:10.1177/2047487320913379.

488

Juocevicius A, Oral A, Lukmann A, et al. Evidence-based position paper on Physical and Rehabilitation Medicine (PRM) professional practice for people with cardiovascular conditions. The European PRM position (UEMS PRM Section). Eur J Phys Rehabil Med. 2018;54(4):634-43. doi:10.23736/S1973-9087.18.05310-8.

489

Иванова Г.Е., Мельникова Е.В., Шмонин А.А. и др. Применение международной классификации функционирования в процессе медицинской реабилитации. Вестник восстановительной медицины. 2018;(6):2-77.

Ivanova GE, Melnikova EV, Shmonin AA, et al. Application of the international classification of functioning in the process of medical rehabilitation. Bulletin of Restorative Medicine. 2018;(6):2-77. (In Russ.)

490

Barber S, Thornicroft G. Reducing the Mortality Gap in People With Severe Mental Disorders: The Role of Lifestyle Psychosocial Interventions. Front Psychiatry. 2018;9:463. doi:10.3389/fpsyt.2018.00463.

491

Hanssen H, Boardman H, Deiseroth A, et al. Personalized exercise prescription in the prevention and treatment of arterial hypertension: a Consensus Document from the European Association of Preventive Cardiology (EAPC) and the ESC Council on Hypertension. Eur J Prev Cardiol. 2022;29(1):205-15. doi:10.1093/eurjpc/zwaa141.

492

Kraus WE, Powell KE, Haskell WL, et al.; 2018 PHYSICAL ACTIVITY GUIDELINES ADVISORY COMMITTEE. Physical Activity, All-Cause and Cardiovascular Mortality, and Cardiovascular Disease. Med Sci Sports Exerc. 2019;51(6):1270-81. doi:10.1249/MSS.0000000000001939.

493

Pescatello LS, Buchner DM, Jakicic JM, et al.; 2018 PHYSICAL ACTIVITY GUIDELINES ADVISORY COMMITTEE*. Physical Activity to Prevent and Treat Hypertension: A Systematic Review. Med Sci Sports Exerc. 2019;51(6):1314-23. doi:10.1249/MSS.0000000000001943.

494

Semlitsch T, Jeitler K, Hemkens LG, et al. Increasing physical activity for the treatment of hypertension: a systematic review and meta-analysis. Sports Med. 2013;43(10):1009- 23. doi:10.1007/s40279-013-0065-6.

495

Fletcher GF, Ades PA, Kligfield P, et al.; American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology, Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. 2013;128(8):873-934. doi:10.1161/CIR.0b013e31829b5b44.

496

Lu Z, Song Y, Chen H, et al. A Mixed Comparisons of Aerobic Training With Different Volumes and Intensities of Physical Exercise in Patients With Hypertension: A Systema - tic Review and Network Meta-Analysis. Front Cardiovasc Med. 2022;8:770975. doi:10.3389/fcvm.2021.770975.

497

Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a metaanalysis of randomized, controlled trials. Ann Intern Med. 2002;136(7):493-503. doi:10.7326/0003-4819-136-7-200204020-00006.

498

Inder JD, Carlson DJ, Dieberg G, et al. Isometric exercise training for blood pressure management: a systematic review and meta-analysis to optimize benefit. Hypertens Res. 2016;39(2):88-94. doi:10.1038/hr.2015.111.

499

Borg G. Psychophysical scaling with applications in physical work and the perception of exertion. Scand J Work Environ Health. 1990;16 Suppl 1:55-8. doi:10.5271/sjweh.1815.

500

Duan Y, Xie Z, Dong F, et al. Effectiveness of home blood pressure telemonitoring: a systematic review and meta-analysis of randomised controlled studies. J Hum Hypertens. 2017;31(7):427-437. doi:10.1038/jhh.2016.99.

501

Bray EP, Holder R, Mant J, McManus RJ. Does self-monitoring reduce blood pressure? Meta-analysis with meta-regression of randomized controlled trials. Ann Med. 2010; 42(5):371-86. doi:10.3109/07853890.2010.489567.

502

Niiranen TJ, Hänninen MR, Johansson J, et al. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: the Finn-Home study. Hypertension. 2010;55(6):1346-51. doi:10.1161/HYPERTENSIONAHA.109.149336.

503

Leshchuk TY. Organizatsionno-profilakticheskie meropriyatiya po vyyavleniyu skrytykh priznakov arterial’noy gipertenzii. CardioSomatics. 2015;6(1-1):58. (In Russ.) Лещук Т.Ю. Организационно-профилактические мероприятия по выявлению скрытых признаков артериальной гипертензии. CardioСоматика. 2015;6(1-1):58.

Leshchuk TY. Organizatsionno-profilakticheskie meropriyatiya po vyyavleniyu skrytykh priznakov arterial’noy gipertenzii. CardioSomatics. 2015;6(1-1):58. (In Russ.)

504

Julius S, Nesbitt SD, Egan BM, et al.; Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354(16):1685-97. doi:10.1056/NEJMoa060838.

505

Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334(7599):885-8. doi:10.1136/bmj.39147.604896.55.

506

Fahey T, Schroeder K, Ebrahim S. Educational and organisational interventions used to improve the management of hypertension in primary care: a systematic review. Br J Gen Pract. 2005;55(520):875-82.

507

Glynn LG, Murphy AW, Smith SM, et al. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2010;(3): CD005182. doi:10.1002/14651858.CD005182.pub4.

508

Birtwhistle RV, Godwin MS, Delva MD, et al. Randomised equivalence trial comparing three month and six month follow up of patients with hypertension by family practitioners. BMJ. 2004;328(7433):204. doi:10.1136/bmj.37967.374063.EE.

509

Omboni S, Gazzola T, Carabelli G, Parati G. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens. 2013;31(3):455-67; discussion 467-8. doi:10.1097/HJH.0b013e32835ca8dd.

510

Omboni S, Ferrari R. The role of telemedicine in hypertension management: focus on blood pressure telemonitoring. Curr Hypertens Rep. 2015;17(4):535. doi:10.1007/s11906-015-0535-3.

511

Ткачева О.Н., Рунихина Н.К., Остапенко В.С. и др. Валидация опросника для скрининга синдрома старческой астении в амбулаторной практике. Успехи геронтологии. 2017;30(2):236-42. EDN YQGBWZ

Tkacheva ON, Runikhina NK, Ostapenko VS, et al. Validation of the questionnaire for screening of senile asthenia syndrome in outpatient practice. The successes of gerontology. 2017;30(2):236-42. (In Russ.) EDN YQGBWZ

512

Sehestedt T, Jeppesen J, Hansen TW, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J. 2010 Apr;31(7):883- 91. doi:10.1093/eurheartj/ehp546. Erratum in: Eur Heart J. 2010;31(13):1662. TorpPetersen, Christian [corrected to Torp-Pedersen, Christian].

The authors declare that there are no conflicts of interest present.